The BIS-linked Project Agorá is moving to real-value testing, aimed at settlement using tokenized central bank money and bank deposits.
The project, backed by major central banks, is “now” proceeding toward testing that uses real-world value rather than limited pilots. The focus is operational: whether tokenized forms of central bank money and bank deposits can settle on blockchain rails in a way that is fast and reliable enough for cross-border payment workflows.
Why it matters
For cross-border payments, settlement speed and counterparty risk matter as much as messaging and trading. Project Agorá’s next step targets the settlement layer. If “real-value” testing bears out the project’s assumptions, tokenization could reduce friction between intermediaries by changing how money and deposits move and settle.
It also signals that official-sector experiments are shifting from proof-of-concept to something closer to production constraints. That includes how assets behave under operational load, how participants coordinate settlement, and whether the system holds up when actual value is on the line.
Market impact
This is not a token-market rollout. Project Agorá is about tokenizing central bank money and bank deposits, which are different assets from retail crypto tokens.
Still, the project points toward a policy direction that could shape future product design for banks and payment providers. It also adds pressure to firms building blockchain settlement infrastructure to support regulated asset types and institutional workflow requirements.
What to watch next
The next milestone is the details and scope of the “real-value” testing. Readers should look for:
- Which central banks and banks participate in the testing.
- What “tokenized central bank money” and “bank deposits” mean in the project’s implementation.
- The settlement performance criteria used in the test.
- Whether results lead to further phased rollouts or limit the scope.
The desk expects more concrete reporting as the testing plan takes shape, since this stage is where operational reality can either validate or undercut prior trial findings.